天士力：2025年归母净利润同比增长15.68%

Core Viewpoint - Tianjin Tasly Pharmaceutical (600535) reported a net profit of 1.105 billion yuan for the year 2025, representing a year-on-year increase of 15.68% [1] - The company achieved a basic earnings per share of 0.74 yuan, also reflecting a year-on-year growth of 15.63% [1] Group 1: Company Developments - In 2025, the company officially became a member of China Resources Sanjiu (000999), marking the beginning of a new chapter in integrated development driven by innovation [1] - The company successfully completed the "100-day integration" with China Resources Sanjiu and is steadily advancing the "first-year integration" initiatives [1] Group 2: Business Focus and Strategy - The company is focusing on three major therapeutic areas: cardiovascular and metabolic, neurological/psychiatric, and digestive health, in response to the impact of centralized procurement and cost control policies in the pharmaceutical industry [1] - The company aims to enhance its core business and overall efficiency, competitiveness, and effectiveness, adhering to an innovation-driven approach to achieve high-quality development [1] - The long-term goal is to become a leading enterprise in the Chinese pharmaceutical market [1]